JP2022513700A5 - - Google Patents
Info
- Publication number
- JP2022513700A5 JP2022513700A5 JP2021531492A JP2021531492A JP2022513700A5 JP 2022513700 A5 JP2022513700 A5 JP 2022513700A5 JP 2021531492 A JP2021531492 A JP 2021531492A JP 2021531492 A JP2021531492 A JP 2021531492A JP 2022513700 A5 JP2022513700 A5 JP 2022513700A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774847P | 2018-12-03 | 2018-12-03 | |
| US62/774,847 | 2018-12-03 | ||
| PCT/IB2019/001342 WO2020115556A1 (en) | 2018-12-03 | 2019-12-03 | Radioimmunoconjugates and checkpoint inhibitor combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513700A JP2022513700A (ja) | 2022-02-09 |
| JPWO2020115556A5 JPWO2020115556A5 (https=) | 2023-10-25 |
| JP2022513700A5 true JP2022513700A5 (https=) | 2023-10-25 |
Family
ID=70973593
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531492A Pending JP2022513700A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とチェックポイント阻害剤の併用療法 |
| JP2021531486A Pending JP2022511471A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
| JP2024193520A Pending JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531486A Pending JP2022511471A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
| JP2024193520A Pending JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20220088231A1 (https=) |
| EP (2) | EP3890789A4 (https=) |
| JP (3) | JP2022513700A (https=) |
| KR (2) | KR20210099073A (https=) |
| CN (4) | CN117482261A (https=) |
| AU (2) | AU2019394888A1 (https=) |
| BR (2) | BR112021010670A2 (https=) |
| CA (2) | CA3119917A1 (https=) |
| CL (2) | CL2021001432A1 (https=) |
| EA (2) | EA202191556A1 (https=) |
| IL (2) | IL283613A (https=) |
| MA (2) | MA54401A (https=) |
| MX (2) | MX2021006408A (https=) |
| PE (2) | PE20211286A1 (https=) |
| PH (2) | PH12021551282A1 (https=) |
| SG (2) | SG11202105112RA (https=) |
| WO (2) | WO2020115548A1 (https=) |
| ZA (1) | ZA202103429B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020142583A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| CR20210556A (es) | 2019-05-10 | 2021-12-17 | Janssen Biotech Inc | Quelantes macrocíclicos y métodos de uso de estos |
| WO2021142231A1 (en) * | 2020-01-10 | 2021-07-15 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
| WO2021207086A1 (en) * | 2020-04-06 | 2021-10-14 | Fusion Pharmaceuticals Inc. | Tem-1-targeted radioimmunoconjugates and uses thereof |
| CN119792512A (zh) | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| US20250275946A1 (en) * | 2021-02-02 | 2025-09-04 | Unm Rainforest Innovations | Combination therapy for the treatment of cancer |
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| US20250339571A1 (en) * | 2021-08-27 | 2025-11-06 | Actinium Pharmaceuticals, Inc. | Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer |
| CA3233733A1 (en) * | 2021-09-29 | 2023-04-06 | National Research Council Of Canada | Egfrviii-targeted compounds and uses thereof |
| TW202325344A (zh) * | 2021-11-02 | 2023-07-01 | 加拿大商融合製藥公司 | 治療癌症之方法 |
| CA3249955A1 (en) * | 2022-01-28 | 2023-08-03 | Fusion Pharmaceuticals Inc. | Polytherapy based on radiopharmaceuticals targeting NTSR1 and DNA damage response inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US7736651B1 (en) * | 2000-11-24 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
| ES2408704T3 (es) * | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
| US7612178B2 (en) * | 2006-03-28 | 2009-11-03 | Biogen Idec Ma Inc | Anti-IGF-1R antibodies and uses thereof |
| WO2011060233A1 (en) * | 2009-11-11 | 2011-05-19 | The Trustees Of The University Of Pennsylvania | Anti-tem1 antibodies and uses thereof |
| ES2978177T3 (es) * | 2009-12-02 | 2024-09-06 | Immunomedics Inc | Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| SI3134127T1 (sl) * | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| EP3280439A1 (en) * | 2015-04-07 | 2018-02-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anti-pd-l1 immunotoxin for use in therapy |
| US10702526B2 (en) * | 2015-04-20 | 2020-07-07 | Effector Therapeutics Inc. | Inhibitors of immune checkpoint modulators and related methods |
| WO2016172249A1 (en) * | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| EP3303398A1 (en) * | 2015-05-29 | 2018-04-11 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| ES2875747T3 (es) * | 2016-01-11 | 2021-11-11 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia |
| EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| TWI755395B (zh) * | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| US11633506B2 (en) * | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| EP3496707A4 (en) | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| WO2018038680A1 (en) * | 2016-08-24 | 2018-03-01 | Scinopharm Taiwan, Ltd. | Processes for preparing olaparib |
| KR20190053909A (ko) * | 2016-09-16 | 2019-05-20 | 바이오노믹스 리미티드 | 항체와 체크포인트 면역 억제제의 병용 요법 |
| BR112019011794A2 (pt) * | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| EP3585436A1 (en) * | 2017-02-24 | 2020-01-01 | Bayer AS | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| KR102612882B1 (ko) * | 2017-05-05 | 2023-12-11 | 센터 포 프로브 디벨롭먼트 앤드 커머셜리제이션 | 이관능성 킬레이트 및 그의 용도의 약동학적 증진 |
| CA3062538A1 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| JP2020533002A (ja) * | 2017-09-13 | 2020-11-19 | ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | メラニン抗体及びその使用 |
| CN111372613A (zh) * | 2017-11-22 | 2020-07-03 | 诺帝克纳诺维科特公司 | 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤 |
| CA3130747A1 (en) * | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
-
2019
- 2019-12-03 EA EA202191556A patent/EA202191556A1/ru unknown
- 2019-12-03 US US16/619,433 patent/US20220088231A1/en active Pending
- 2019-12-03 MX MX2021006408A patent/MX2021006408A/es unknown
- 2019-12-03 SG SG11202105112RA patent/SG11202105112RA/en unknown
- 2019-12-03 MX MX2021006407A patent/MX2021006407A/es unknown
- 2019-12-03 CN CN202311139310.7A patent/CN117482261A/zh active Pending
- 2019-12-03 CN CN202510572446.XA patent/CN120393061A/zh active Pending
- 2019-12-03 AU AU2019394888A patent/AU2019394888A1/en active Pending
- 2019-12-03 PE PE2021000815A patent/PE20211286A1/es unknown
- 2019-12-03 MA MA054401A patent/MA54401A/fr unknown
- 2019-12-03 EP EP19892173.6A patent/EP3890789A4/en active Pending
- 2019-12-03 JP JP2021531492A patent/JP2022513700A/ja active Pending
- 2019-12-03 BR BR112021010670-7A patent/BR112021010670A2/pt unknown
- 2019-12-03 CN CN201980079758.XA patent/CN113474014A/zh active Pending
- 2019-12-03 CA CA3119917A patent/CA3119917A1/en active Pending
- 2019-12-03 BR BR112021010799-1A patent/BR112021010799A2/pt not_active Application Discontinuation
- 2019-12-03 PE PE2021000808A patent/PE20211961A1/es unknown
- 2019-12-03 SG SG11202105192WA patent/SG11202105192WA/en unknown
- 2019-12-03 EA EA202191557A patent/EA202191557A1/ru unknown
- 2019-12-03 KR KR1020217020517A patent/KR20210099073A/ko not_active Ceased
- 2019-12-03 KR KR1020217020519A patent/KR20210099074A/ko not_active Ceased
- 2019-12-03 WO PCT/IB2019/001292 patent/WO2020115548A1/en not_active Ceased
- 2019-12-03 CA CA3119915A patent/CA3119915A1/en active Pending
- 2019-12-03 MA MA054399A patent/MA54399A/fr unknown
- 2019-12-03 WO PCT/IB2019/001342 patent/WO2020115556A1/en not_active Ceased
- 2019-12-03 AU AU2019393257A patent/AU2019393257A1/en active Pending
- 2019-12-03 US US16/619,432 patent/US11446401B2/en active Active
- 2019-12-03 JP JP2021531486A patent/JP2022511471A/ja active Pending
- 2019-12-03 CN CN201980079705.8A patent/CN113164632A/zh active Pending
- 2019-12-03 EP EP19893184.2A patent/EP3890790A4/en active Pending
-
2021
- 2021-05-20 ZA ZA2021/03429A patent/ZA202103429B/en unknown
- 2021-05-28 PH PH12021551282A patent/PH12021551282A1/en unknown
- 2021-05-28 PH PH12021551237A patent/PH12021551237A1/en unknown
- 2021-06-01 CL CL2021001432A patent/CL2021001432A1/es unknown
- 2021-06-01 CL CL2021001433A patent/CL2021001433A1/es unknown
- 2021-06-01 IL IL283613A patent/IL283613A/en unknown
- 2021-06-01 IL IL283598A patent/IL283598A/en unknown
- 2021-06-02 US US17/337,357 patent/US20210290789A1/en active Pending
- 2021-06-02 US US17/337,358 patent/US20210290788A1/en active Pending
-
2022
- 2022-08-15 US US17/819,911 patent/US20230270895A1/en not_active Abandoned
-
2024
- 2024-11-05 JP JP2024193520A patent/JP2025013486A/ja active Pending